RANI Earnings Prediction
The chart below shows how RANI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RANI sees a +3.27% change in stock price 10 days leading up to the earnings, and a -5.09% change 10 days following the report. On the earnings day itself, the stock moves by -0.19%. This data can give you a slight idea of what to expect for the next quarter's release.
RANI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.27
-22.86%
-25.00%
No Data Available
RANI Earnings Analysis
Rani Therapeutics Holdings, Inc. Corporation (RANI.O) Earnings Conference Call
Positive
- Successful completion of the Phase 1 trial for RT-111, an orally administered ustekinumab biosimilar, achieving high bioavailability in humans with no serious adverse events mentioned in the call.
- The bioavailability of RT-111 was reported to be 84% via the Rani route of administration compared to subcutaneous injection.
- RT-111 was well tolerated by all participants with no serious adverse events observed.
- Expansion of partnerships with Celltrion for the RT-111 and RT-105 programs, showcasing the commercial potential of Rani's technology in delivering biologics orally.
- results from the first Phase 1 trial for RT-111 led to an expansion of the partnership with Celltrion.
- Successful oral delivery of adalimumab in preclinical studies using the RaniPill HC device.
- Potential impact of RaniPill in treating obesity with preclinical data demonstrating rapid weight loss with GIP and glucagon triagonists.
- Capability of RaniPill to deliver multiple obesity treatments orally.
- Obesity market expected to exceed $100 billion by 2030, indicating a significant opportunity for Rani Therapeutics.
- Financial stability and strategic approach to raise additional capital through equity offerings, debt financing, and potential licensing fees to support operations into 2025.
- Cash, cash equivalents, and marketable securities totaling $48.5 million as of December 31, 2023, expected to fund operations into 2025.
- Strict management of operating costs in 2023 while successfully advancing key programs like RT-111 and the RaniPill HC device.
Negative
- The cash, cash equivalents, and marketable securities decreased from $98.5 million in December 2022 to $48.5 million in December 2023, indicating a decline in financial resources.
- Rani Therapeutics recognizes the need to raise additional capital to support operations beyond 2025, suggesting potential financial challenges in the future.
- The net loss for the full year 2023 increased to $67.9 million compared to $63.3 million in 2022, potentially indicating financial strain.
- Research and development expenses for the full year 2023 increased to $39.6 million from $36.6 million in the previous year, highlighting growing operational costs.
- General and administrative expenses remained relatively high at $26.5 million for the full year 2023, with a slight decrease compared to the previous year, potentially impacting profitability.
